UK Shareholder Meetings Calendar - Next 7 Days
UK Shareholder Meetings Calendar - Next 7 Days
Read moreThu, 03rd Nov 2016 11:40
UK Shareholder Meetings Calendar - Next 7 Days
Read more(Sharecast News) - Clinical-stage biotechnology company ValiRx updated the market on its subsidiary joint venture, ValiSeek, and its cancer therapeutic, VAL401 on Tuesday.
Read moreValiRx Joint Venture Partner Enters Agreement For VAL401 Funding
Read moreValiRx Raises GBP200,000 To Progress Product Development
Read moreValiRx Reveals "Clear Impact" Of VAL201 On Prostate Cancer Patients
Read more(Sharecast News) - Clinical stage biotechnology company ValiRx announced on Thursday that the US Patent and Trademark Office has granted patent number 10,400,008, titled 'Modulators Of The SRC-Kinase Activity For Preventing Or Treating Metastatic Cancer', to its lead therapeutic compound 'VAL201'.
Read moreValiRx Granted "Key" US Patent Protection For VAL201 Cancer Treatment
Read moreValiRx Raises GBP350,000 Through Placing To Progress Clinical Trials
Read moreValiRx Reports Narrowed Loss In First Half As Expenses Reduce
Read moreValiRx Receives GBP423,000 Research & Development Credit From UK HMRC
Read more(Alliance News) - ValiRx PLC on Tuesday said its VAL201 lead compound is still meeting all of its published endpoints and is behaving as expected in prostate cancer.VAL201 has been as a and
Read more(Alliance News) - Clinical stage biotechnology firm ValiRx PLC said Thursday it has been granted a patent notice of allowance for its pre-clinical therapeutic compound, VAL301, from the European a
Read more(Alliance News) - ValiRx PLC on Tuesday said Monecor London Ltd now holds 5.7% interest in the biotechnology company.Prior to this transaction on Monday, Monecor's holding totalled were
Read more(Alliance News) - ValiRx PLC on Wednesday said the US has allowed a patent claim for the use of VAL201 in metastatic cancer.Shares in ValiRx were down 7.1% at 0.21 pence in afternoon trade
Read more(Sharecast News) - Clinical stage biotechnology company ValiRx announced on Wednesday that the US Patent and Trademark Office (USPTO) has allowed patent claims directed towards a method of preventing the worsening of symptoms of metastatic cancer, reducing the progression of metastatic cancer, or treating metastatic cancer - including prostate cancer - by administration of the 'VAL201' peptide.
Read more